Hero image of three physicians

Drug-Eluting Technologies - DET

More evidence. More confidence.
More successful outcomes.

Drug-eluting stents (DESs) are used in the treatment of atherosclerosis in both coronary interventions and peripheral arterial interventions. Explore our Drug-Eluting technologies.

Eluvia™ Drug-Eluting Stent DES

Our commitment to addressing restenosis

Eluvia™ Drug-Eluting Stent (DES) Ranger™ Drug-coated Balloon (DCB) and give their patients the very best chance of achieving and maintaining patency in the superficial femoral artery (SFA).

Learn more on Drug-Eluting Technologies
Eluvia™ Drug-Eluting Stent DES

The new standard of care for long complex lesions

Eluvia™ Drug-Eluting Stent is designed to meet the challenges of the superficial femoral artery (SFA), providing sustained drug release for up to 12 months, unlike other drug-eluting stents which only release it for 2-3 months.

Learn more on Eluvia Drug-Eluting Stent
Clinical Studies

Standing on evidence in SFA interventions

Enrolling over 10,000 patients globally in multiple head-to-head randomised controlled trials and real-world registries, Boston Scientific is giving physicians evidence-based tools to take the fight to PAD.

Learn more on clinical studies
SFA treatment

Dive into SFA treatments

Get more information about Peripheral Artery Disease (PAD) and its challenges to better understand  the various treatment options for superficial femoral artery through our drug-eluting therapies in vascular surgery.

Learn more on SFA treatment

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.